Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.

Several mitogen-activated protein kinase (MAPK) signaling inhibitors are currently undergoing clinical trial as part of novel mechanism-based anticancer treatment strategies. This study was aimed at detecting biomarkers of MAPK signaling inhibition in human breast and colon carcinoma cells using magnetic resonance spectroscopy. We investigated the effect of the prototype MAPK kinase inhibitor U0126 on the (31)P-MR spectra of MDA-MB-231, MCF-7 and Hs578T breast, and HCT116 colon carcinoma cells. Treatment of MDA-MB-231 cells with 50 micromol/L U0126 for 2, 4, 8, 16, 24, 32, and 40 hours caused inhibition of extracellular signal-regulated kinases (ERK1/2) phosphorylation from 2 hours onwards. (31)P-MR spectra of extracted cells indicated that this was associated with a significant drop in phosphocholine levels to 78 +/- 8% at 8 hours, 74 +/- 8% at 16 hours, 66 +/- 7% at 24 hours, 71 +/- 10% at 32 hours, and 65 +/- 10% at 40 hours post-treatment. In contrast, the lower concentration of 10 micromol/L U0126 for 40 hours had no significant effect on either P-ERK1/ 2 or phosphocholine levels in MDA-MB-231 cells. Depletion of P-ERK1/2 in MCF-7 and Hs578T cells with 50 micromol/L U0126 also produced a drop in phosphocholine levels to 51 +/- 17% at 40 hours and 23 +/- 12% at 48 hours, respectively. Similarly, in HCT116 cells, inhibition with 30 micromol/L U0126 caused depletion of P-ERK1/2 and a decrease in phosphocholine levels to 80 +/- 9% at 16 hours and 61 +/- 4% at 24 hours post-treatment. The reduction in phosphocholine in MDA-MB-231 and HCT116 cells correlated positively with the drop in P-ERK1/2 levels. Our results show that MAPK signaling inhibition with U0126 is associated with a time-dependent decrease in cellular phosphocholine levels. Thus, phosphocholine has potential as a noninvasive pharmacodynamic marker for monitoring MAPK signaling blockade.

[1]  D. Megías,et al.  Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression , 2004, Cancer Research.

[2]  E. Eisenhauer,et al.  Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. , 2004, Journal of the National Cancer Institute.

[3]  R. Götz,et al.  Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure , 2004, BMC Cancer.

[4]  J. Griffiths,et al.  Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. , 2003, Journal of the National Cancer Institute.

[5]  E. Collisson,et al.  Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. , 2003, Cancer research.

[6]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[7]  D. Vance,et al.  Oncogenic Ha-Ras Transformation Modulates the Transcription of the CTP:Phosphocholine Cytidylyltransferase α Gene via p42/44MAPK and Transcription Factor Sp3* , 2003, The Journal of Biological Chemistry.

[8]  P. Workman.  How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.

[9]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[10]  D. Strumberg,et al.  The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer , 2002, Oncology Research and Treatment.

[11]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[12]  P. Workman.  Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.

[13]  L. Siu,et al.  Rationale for Ras and raf-kinase as a target for cancer therapeutics. , 2002, Current pharmaceutical design.

[14]  S. Osman,et al.  Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin , 2002, British Journal of Cancer.

[15]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[16]  J. Sebolt-Leopold,et al.  Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. , 2002, Trends in molecular medicine.

[17]  A. Adjei,et al.  Ras signaling pathway proteins as therapeutic targets. , 2001, Current pharmaceutical design.

[18]  A. Ramírez de Molina,et al.  Targeting new anticancer drugs within signalling pathways regulated by the Ras GTPase superfamily (Review). , 2001, International journal of oncology.

[19]  R. Tapping,et al.  BMK1 Mediates Growth Factor-induced Cell Proliferation through Direct Cellular Activation of Serum and Glucocorticoid-inducible Kinase* , 2001, The Journal of Biological Chemistry.

[20]  M. White,et al.  ERK5 and ERK2 Cooperate to Regulate NF-κB and Cell Transformation* , 2001, The Journal of Biological Chemistry.

[21]  M. Leach,et al.  Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells , 2001, British Journal of Cancer.

[22]  J. Sebolt-Leopold.  Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[23]  J. Gutkind,et al.  Multiple Mitogen-Activated Protein Kinase Signaling Pathways Connect the Cot Oncoprotein to the c-junPromoter and to Cellular Transformation , 2000, Molecular and Cellular Biology.

[24]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[25]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[26]  F. Podo.  Tumour phospholipid metabolism , 1999, NMR in biomedicine.

[27]  A. Harris,et al.  Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.

[28]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[29]  A. Stringaro,et al.  Biophysical and structural characterization of 1H-NMR-detectable mobile lipid domains in NIH-3T3 fibroblasts. , 1999, Biochimica et biophysica acta.

[30]  T. Powles,et al.  Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment , 1998, NMR in biomedicine.

[31]  Channing J Der,et al.  Increasing complexity of Ras signaling , 1998, Oncogene.

[32]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[33]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[34]  S. Williams,et al.  Immortalization and transformation are associated with specific alterations in choline metabolism. , 1996, Cancer research.

[35]  W. Hull,et al.  31P MRS of human tumor cells: effects of culture media and conditions on phospholipid metabolite concentrations. , 1996, Anticancer research.

[36]  R. Gillies,et al.  Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. , 1996, Anticancer research.

[37]  D. Gadian.  NMR and its Applications to Living Systems , 1996 .

[38]  T. Wieder,et al.  c-Ha-ras oncogene expression increases choline uptake, CTP: phosphocholine cytidylyltransferase activity and phosphatidylcholine biosynthesis in the immortalized human keratinocyte cell line HaCaT. , 1996, Biochimica et biophysica acta.

[39]  H. Degani,et al.  Simultaneous extraction of cellular lipids and water‐soluble metabolites: Evaluation by NMR spectroscopy , 1996, Magnetic resonance in medicine.

[40]  M. Cobb,et al.  Isolation of MEK5 and Differential Expression of Alternatively Spliced Forms * , 1995, The Journal of Biological Chemistry.

[41]  L. del Peso,et al.  Generation of phosphorylcholine as an essential event in the activation of Raf‐1 and MAP‐kinases in growth factors‐induced mitogenic stimulation , 1995, Journal of cellular biochemistry.

[42]  S. Jackowski.  Coordination of membrane phospholipid synthesis with the cell cycle. , 1994, The Journal of biological chemistry.

[43]  F Podo,et al.  In vivo 31P MRS of experimental tumours , 1993, NMR in biomedicine.

[44]  J. Pouysségur,et al.  Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[46]  H Degani,et al.  Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. , 1992, Biochimica et biophysica acta.

[47]  M. Leach,et al.  The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate. , 1991, British Journal of Cancer.

[48]  C. Kent,et al.  Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. , 1990, The Journal of biological chemistry.

[49]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[50]  P. Anderson,et al.  Rapid stimulation of diacylglycerol production in Xenopus oocytes by microinjection of H-ras p21. , 1988, Science.

[51]  S. Aaronson,et al.  Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene , 1987, Nature.

[52]  J. S. Cohen,et al.  Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. , 1987, The Journal of biological chemistry.